Who are romiplostim plus dexamethasone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/romiplostim-plus-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

romiplostim plus dexamethasone — Competitive Intelligence Brief

romiplostim plus dexamethasone (romiplostim plus dexamethasone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombopoietin receptor agonist plus corticosteroid. Area: Hematology/Immunology.

phase 3 Thrombopoietin receptor agonist plus corticosteroid Thrombopoietin receptor (TPO-R); glucocorticoid receptor Hematology/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

romiplostim plus dexamethasone (romiplostim plus dexamethasone) — Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Romiplostim stimulates thrombopoietin receptors to increase platelet production, while dexamethasone provides immunosuppressive and anti-inflammatory effects to treat immune thrombocytopenia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
romiplostim plus dexamethasone TARGET	romiplostim plus dexamethasone	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	phase 3	Thrombopoietin receptor agonist plus corticosteroid	Thrombopoietin receptor (TPO-R); glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombopoietin receptor agonist plus corticosteroid class)

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). romiplostim plus dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/romiplostim-plus-dexamethasone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab